1Regitz V, Shug Al,Fleck E.Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary,hypertensive and valvular heart disease[J]. Am J Cardiol,2001,65:755 - 760.
2Kontor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain- 3-Ketoacy coenzyme A thiolase[J].Circ Tes,2000,86:580-588.
3Tershchenko SN,Drozdov VN,Levchuk NN,et al.Plasma hemostasis and biochemical indices in trimetzidine treatment of patients with chronic heart failure[J].Ter Arkh,1998,70:41-44.
4Chierchia SL.Trimetazidine and lett ventricuiar iscnaeimc dysfunction[J].Eur Heart J,2001,3:16- 20.
